Research

FDA Expands Approval of Ipilimumab For Pediatric Melanoma Patients

August 3, 2017 | Categories: News, Research, Treatment

Last week the United States Food and Drug Administration (FDA) expanded approval of Yervoy (ipilimumab) to include pediatric patients ages 12 years and older with unresectable or metastatic melanoma. Yervoy, a monoclonal antibody that activates the immune system by blocking the CTLA-4 receptor, was first approved in 2011 to treat unresectable or metastatic melanoma in adults.

Take Action: Stop the NIH Budget Cuts

March 21, 2017 | Categories: News, Policy, Research

The newly proposed federal budget would cut $5.8 billion from the National Institutes of Health (NIH) budget in fiscal year (FY) 2018, which would be a crippling blow to the scientific community.

In Kristin's Words: A Patient Perspective on Research

September 20, 2016 | Categories: News, Ocular Melanoma, Patient Stories, Research

Ocular melanoma patient and advocate Kristin Nocco recently participated in a first-of-its-kind patient review process to determine the recipient of OM research funding.

Summer's Story: The Need for an OM Patient Registry

August 24, 2016 | Categories: Causes, Ocular Melanoma, Patient Stories, Research

Summer shares her ocular melanoma story and why she joined the #CUREOM Unite! campaign to support the development of a national ocular melanoma patient registry.

Children and Melanoma

January 30, 2013 | Categories: Research

Years ago I worked at a hospital for children, raising money for pediatric medical research. The importance of this work was evident every time I walked the halls of the hospital. Seeing young children transported in little red wagons outfitted with IV poles was a powerful motivation to work harder for better therapies and cures.

FDA to Consider Patient Perspective in Drug Development

November 8, 2012 | Categories: News, Treatment, Research

The FDA is launching a new program in which they will consider and incorporate the patient perspective into drug development.  They will choose 20 diseases for the program and the MRF is lobbying to have melanoma be one of them.  As we all know, the patient perspective is important in any disease, but it is especially true with melanoma. 

Here is my letter to the FDA expressing this great need in the field of melanoma.

A Day With the Doctors

May 14, 2012 | Categories: Ocular Melanoma, Research

I spent the day last week in a meeting with doctors and researchers who gathered to discuss ocular melanoma, or melanoma of the eye.  It was the first bi-annual scientific meeting of CURE OM, the MRF’s program focusing on this rare cancer.  Spending 11 hours discussing the science of this cancer was informative and, frankly, rather exhausting.  Several things struck me about this meeting:

Fighting Dirty

February 8, 2012 | Categories: Events, News, Policy, Prevention, Research

I read the report from Congress’ House Energy and Commerce Committee with great interest.  They used interns to call 300 tanning salons—at least 3 in each state and the District of Columbia—and asked salon staff questions about tanning safety.  Presenting themselves as a 16 year old girl with blond hair and fair skin, they asked if tanning was dangerous and how much they could tan.

Gifts and Giving

December 27, 2011 | Categories: Research

 

A close relative is a two-time cancer survivor.  He was diagnosed with lymphoma, a form of cancer that is notorious for recurrence.  Fortunately the doctors caught it early and rounds of radiation and chemotherapy worked their magic on the tumor.  When he came back for a follow-up check after finishing therapy, they found a spot on his kidney.  He was diagnosed with kidney cancer and had to have that organ removed.  That was over a dozen years ago and he is still NED – no evidence of disease. 

Making the World Go Round

October 24, 2011 | Categories: Research

 

They say that money makes the world go round.  That money talks.  Certainly in the research field, money is the key to progress. 

We can truly say that right now in melanoma research, money is the primary limiting factor impeding progress. 

Pages